Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs will become unsustainable for universal healthcare access. Moreover, early market access of new oncology medicines lacking appropriate clinical evaluation generates uncertainty over their cost-effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisana, Alice, Wettermark, Björn, Kurdi, Amanj, Tubic, Biljana, Pontes, Caridad, Zara, Corinne, Van Ganse, Eric, Petrova, Guenka, Mardare, Ileana, Fürst, Jurij, Roig-Izquierdo, Marta, Melien, Oyvind, Bonanno, Patricia Vella, Banzi, Rita, Marković-Peković, Vanda, Mitkova, Zornitsa, Godman, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295616/
https://www.ncbi.nlm.nih.gov/pubmed/35865969
http://dx.doi.org/10.3389/fphar.2022.873556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295616/
https://www.ncbi.nlm.nih.gov/pubmed/35865969
http://dx.doi.org/10.3389/fphar.2022.873556

Ejemplares similares